Towards A More Predictive Model Of Human Biology: A Fireside Chat

In December 2022, significant research papers were published on the predictive validity in drug discovery and the economic analysis of a human Liver-Chip for predictive toxicology. This coincided with the signing of the FDA Modernization Act 2.0 by President Biden, which permits the use of Organ-on-a-Chip technology data in new drug submissions, thereby replacing the 1938 mandate for animal testing. This has triggered discussions on the industry's future and the application of this novel technology. Experts in the field have begun to explore the significance of predictive validity in drug discovery, the efficacy of the Emulate human Liver-Chip in detecting drugs that may cause liver damage, the possibility of enhancing R&D productivity, and the implications of the FDA Modernization Act 2.0.